Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 57%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health continues to demonstrate strong financial performance with a 7% year-over-year growth, indicating resilience in a challenging market. The company maintains a dominant position in the comprehensive genomic profiling liquid biopsy market with over 50% market share and has experienced nearly 30% year-over-year growth, suggesting robust demand for its diagnostics services. Additionally, the recent advancements in reimbursement and pricing strategies for its Reveal and Shield testing products are expected to drive further expansion in average selling prices and test volumes, enhancing future revenue potential.

Bears say

Guardant Health faces significant challenges due to the potential decrease in reimbursement rates, which could negatively affect its average selling price (ASP) and overall revenue estimates. The outstanding PAMA regulations present a risk of a one-time revenue decline of approximately $100 million, further exacerbating financial uncertainties. Additionally, the regulatory landscape for multi-cancer early detection tests (MCED) remains nascent, leaving Guardant's ability to secure necessary reimbursements and drive adoption of its assays in question.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 57% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.05, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.05, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.